For the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable.
Limitation of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants.
the unrelenting itch and rash
of atopic dermatitis1
Visit the U.S. site to learn
about the efficacy and
safety of RINVOQ
in moderate to severe atopic dermatitis